 |
Differentiating Leg Disorders: Strategies for Diagnosis and Treatment in the Primary Care Setting CME Paul P. Doghramji, MD, FAAFP, Moderator; Emile R. Mohler III, MD; Joyce L. Ross, MSN, RNC, CRNP, CS; John S. Sundy, MD, PhD; Michael J. Thorpy, MD Author Information and Disclosures Release Date: April 21, 2008; Valid for credit through April 21, 2009 | Physicians - maximum of 2.5 AMA PRA Category 1 Credit(s)™ for physicians
Nurse Practitioners - This program has been approved for 2.0 contact hours of continuing education by the American Academy of Nurse Practitioners. Program ID 0801051. | | This CME activity is based on transcripts and slides of presentations as delivered by the panel for the "Differentiating Leg Disorders: Strategies for Diagnosis and Treatment in the Primary Care Setting" educational simulcast originally presented on November 7, 2007.
To participate in this Internet activity: (1) review the target audience, learning objectives, and author disclosures; (2) study the educational content; (3) take the post-test and/or complete the evaluation; (4) view/print certificate View details. Legal DisclaimerThe material presented here does not necessarily reflect the views of Medscape or companies that support educational programming on www.medscape.com. These materials may discuss therapeutic products that have not been approved by the US Food and Drug Administration and off-label uses of approved products. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or employing any therapies described in this educational activity. Copyright © 2008 Professional Postgraduate Services® (PPS) |
|
|
Learning Objectives Upon completion of this activity, participants should be able to: - Describe the clinical presentation, including classic symptomatology and physical examination findings, of neurologic, vascular, and musculoskeletal leg disorders.
- Differentiate between leg disorders based
on pathophysiologic origin to provide proper diagnosis and possible cause of disease.
- Recognize the implications of misdiagnosis of leg disorders and its relative impact on patient outcomes, including morbidity, mortality, and quality of life.
- Design a treatment plan that utilizes pharmacologic and nonpharmacologic strategies to manage the symptoms and comorbidities associated with leg disorders.
Author Disclosures Paul P. Doghramji, MD, FAAFP
Collegeville Family Practice, Pottstown Medical Specialists, Inc; Medical Director of Health Services, Ursinus College, Collegeville, PA; Assistant Medical Director, Hill School, Pottstown, PA
Disclosure: Consultant: Cephalon, Inc., sanofi-aventis, Takeda Pharmaceuticals
North America, Inc.; Speakers' Bureau: Cephalon, Inc., Pfizer Inc, sanofi-aventis, Takeda Pharmaceuticals North America, Inc., Wyeth; Stockholder: Pfizer Inc, Wyeth
Emile R. Mohler III, MD
Associate Professor of Medicine, Department of Medicine, University of Pennsylvania School of Medicine; Director, Vascular Medicine, University of Pennsylvania Health System, Philadelphia, PA
Disclosure: Grant/Research Support:
GlaxoSmithKline; sanofi-aventis/Bristol-Myers Squibb; Speakers' Bureau: AstraZeneca, Merck & Co., Inc., sanofi-aventis/Bristol-Myers Squibb
Joyce L. Ross, MSN, RNC, CRNP, CS
Adjunct Faculty, Gwynedd-Mercy College, Gwynedd Valley, PA; Guest Instructor and Clinical Preceptor, University of Pennsylvania; Nurse Practitioner Program, Temple University, Philadelphia, PA
Disclosure: Speakers' Bureau: Abbott
Laboratories, AstraZeneca, Kaneka America LLC, Pfizer Inc
John S. Sundy, MD, PhD
Associate Professor of Medicine, Division of Pulmonary Allergy and Critical Care Medicine, Division of Rheumatology and Immunology, Department of Medicine, Duke University School of Medicine; Medical Director, Allergen Immunotherapy and Skin Test Laboratory; Head, Section of Allergy and Clinical Immunology, Duke University Medical Center, Durham,
NC
Disclosure: Grant/Research Support: GlaxoSmithKline, Mannkind Corporation, Savient Pharmaceuticals, Inc.; Consultant: Novartis; Stockholder: General Electric
Michael J. Thorpy, MD
Professor of Neurology, Albert Einstein College of Medicine; Director, Sleep-Wake Disorders Center, Montefiore Medical Center, Bronx, NY
Disclosure: Speakers' Bureau: Boehringer Ingelheim, GlaxoSmithKline
Kimberly Andrews
Senior Program Director, Professional Postgraduate Services®, Secaucus, NJ
Disclosure: No relevant financial relationships to disclose
Genevieve Blazini
Executive Editor, Professional Postgraduate Services®, Secaucus, NJ
Disclosure: No relevant financial relationships to disclose
Megan Tierney
Program Director, Professional Postgraduate Services®, Secaucus, NJ
Disclosure: No relevant financial relationships to disclose
Wadee'ah Terry
CME Program Manager, Professional Postgraduate Services®, Secaucus, NJ
Disclosure: No relevant financial relationships to disclose
Liz Ward
Director of CME, Professional Postgraduate
Services®, Secaucus, NJ
Disclosure: No relevant financial relationships to disclose
|
 |
Professional Postgraduate Services ® is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Professional Postgraduate Services ® designates this educational activity for a maximum of 2.5 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity. For Nurse Practitioners
This program has been approved for 2.0 contact hours of continuing education by
the American Academy of Nurse Practitioners. Program ID 0801051.
Contact This Provider
|
|
